Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has …
Over the last 12 months, insiders at Innoviva, Inc. have bought $0 and sold $0 worth of Innoviva, Inc. stock.
On average, over the past 5 years, insiders at Innoviva, Inc. have bought $4.38M and sold $130.77M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 62,000 shares for transaction amount of $814,196 was made by DENNER ALEXANDER J (10 percent owner) on 2023‑06‑15.
2023-11-15 | Sale | Chief Accounting Officer | 10,994 0.0173% | $13.99 | $153,810 | +15.23% | ||
2023-06-15 | 10 percent owner | 62,000 0.0912% | $13.13 | $814,196 | +11.20% | |||
2023-06-06 | 10 percent owner | 8,000 0.0118% | $13.05 | $104,384 | +10.38% | |||
2023-06-05 | 10 percent owner | 7,000 0.0102% | $13.04 | $91,297 | +9.09% | |||
2023-05-30 | 10 percent owner | 120,000 0.1775% | $13.01 | $1.56M | +7.09% | |||
2023-05-26 | 10 percent owner | 30,000 0.0442% | $13.12 | $393,729 | +5.71% | |||
2023-05-25 | 10 percent owner | 50,000 0.0735% | $13.09 | $654,330 | +5.62% | |||
2023-05-19 | 10 percent owner | 36,000 0.0531% | $13.48 | $485,147 | +1.71% | |||
2023-05-18 | 10 percent owner | 10,000 0.0146% | $13.05 | $130,538 | +3.77% | |||
2023-05-17 | 10 percent owner | 50,000 0.0736% | $13.07 | $653,690 | +4.46% | |||
2023-05-11 | 10 percent owner | 290,000 0.4246% | $12.34 | $3.58M | +9.90% | |||
2023-03-10 | Chief Executive Officer | 3,000 0.0045% | $10.87 | $32,603 | +22.61% | |||
2021-08-20 | Sale | Chief Accounting Officer | 1,129 0.0016% | $15.89 | $17,940 | +3.07% | ||
2021-08-19 | Sale | Chief Accounting Officer | 2,802 0.004% | $16.02 | $44,888 | +2.50% | ||
2021-05-24 | director | 10,000 0.0112% | $13.46 | $134,619 | +21.34% | |||
2021-05-21 | director | 10,000 0.0111% | $12.97 | $129,670 | +24.75% | |||
2021-05-20 | Sale | 10 percent owner | 32.01M 33.288% | $12.25 | $392.06M | +23.35% | ||
2020-02-24 | Sale | Chief Accounting Officer | 2,954 0.003% | $14.78 | $43,660 | -14.60% | ||
2019-02-27 | director | 15,000 0.0148% | $15.90 | $238,500 | -13.22% | |||
2019-02-26 | Sale | Chief Accounting Officer | 5,617 0.0055% | $16.00 | $89,872 | -13.92% |
DENNER ALEXANDER J | 10 percent owner | 7277000 11.6244% | $19.04 | 10 | 0 | +6.89% |
Winningham Rick E | Chief Executive Officer | 690106 1.1024% | $19.04 | 1 | 10 | +19.65% |
Shafer Bradford J | Sr VP, Gen. Counsel, Secretary | 446274 0.7129% | $19.04 | 1 | 9 | <0.0001% |
GLICK MARTY | Executive VP, Finance and CFO | 267805 0.4278% | $19.04 | 1 | 0 | <0.0001% |
BLUM LEONARD M | Sr VP, Chief Comm. Officer | 158618 0.2534% | $19.04 | 3 | 0 | +41.56% |
BlackRock | $154.57M | 16.24 | 10.14M | -2.03% | -$3.2M | <0.01 | |
Sarissa Capital Management LP | $110.9M | 11.65 | 7.28M | 0% | +$0 | 19.4 | |
The Vanguard Group | $95.8M | 10.07 | 6.29M | -6.35% | -$6.5M | <0.01 | |
Franklin Templeton Investments | $95.58M | 10.04 | 6.27M | +13,628.29% | +$94.88M | 0.03 | |
Dimensional Fund Advisors | $70.31M | 7.39 | 4.61M | +2.13% | +$1.47M | 0.02 |